Document Classification

Section Type: RESULTS

Text: A subsequent post hoc analysis by asthma severity revealed significant clinical benefits in actively treated subjects with moderate, persistent asthma at baseline [401-800g budesonide/day (n = 175)], with greater achievement of well-controlled asthma (80. 5 % and 66. 1 % for the active treatment and placebo groups, respectively ; P = 0. 021) and totally controlled asthma (54. 0 % and 33. 9 %, respectively, P = 0. 008), a higher percentage of patients with an asthma control questionnaire score < 0. 75 (56. 6 % and 40. 0 %, respectively ; P = 0. 039) and a greater mean reduction in inhaled corticosteroid use (218. 5 g and 126. 2 g, respectively ; P = 0. 004).